CDC, About Antimicrobial Resistance
Antibiotic Resistance Threatens Everyone. Antibiotic resistance has the potential to affect people at any stage of life, as well as the healthcare, veterinary, and agriculture industries, making it one of the world’s most urgent public health problems. Each year in the U.S., at least 2 million people are infected with antibiotic-resistant bacteria, and at least 23,000 people die as a result.
With few new antibiotics being developed, we must adapt and make smarter use of the effective antibiotics we have left. To do so requires shifting from the current paradigm of one disease- one drug, to a precision medicine paradigm for infectious disease. Testing each infection to determine, at a molecular level, which antibiotic will be most effective.
Shield Diagnostics is driving the necessary paradigm shift to targeted precision therapy through the development of rapid and accurate molecular antibiotic susceptibility testing for those infections which pose the greatest threat of acquiring total antibiotic resistance.
With 820,000 estimated infections of Gonorrhea each year in the US, of which 240,000 are resistant to one or more antibiotics, the CDC has declared antibiotic-resistant Gonorrhea a top three urgent public health threat. The current recommended regime of antibiotics is our last line of defense and resistance has already begun. To be cured of super Gonorrhea, patients have had to be hospitalized for days and treated with toxic, broad-spectrum antibiotics.
Shield’s first flagship product, Target-NG, tests Gonorrhea infections for antibiotic susceptibility to ciprofloxacin, an inexpensive, oral antibiotic, sparing the last line of defense for only the minority of infections which truly need it. Target-NG is a reflex to an initial Gonorrhea & Chlamydia test, both of which are offered as a service from our CLIA certified laboratory.